United Therapeutics Corporation Common Stock (UTHR)

About UTHR

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat p…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1,400

Website

www.unither.com/

Fundamentals

1-day range

$513.72$530.5

Market cap

$21.92B

P/E (trailing)

17.03

P/E (forward)

17.16

EPS (trailing)

$27.96

Dividend yield

—

Beta

0.50

Avg. volume

503.9K

Forecasts

12 analyst ratings

United Therapeutics Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• UTHR

  United Therapeutics Corporation Common Stock

  $515.57

  ▼ 2.34%
  Market cap $21.92BP/E 17.03
  $302.19$609.35
• INSM

  Insmed Incorporated Common Stock

  $118.52

  ▼ 2.36%
  Market cap $21.34BP/E —
  $90.39$212.75
• VTRS

  Viatris Inc. Common Stock

  $16.34

  ▼ 3.26%
  Market cap $20.53BP/E —
  $9.43$18.39
• ROIV

  Roivant Sciences Ltd. Common Shares

  $34.71

  ▼ 7.64%
  Market cap $24.08BP/E —
  $11.85$37.97
• JAZZ

  Jazz Pharmaceuticals plc Common Stock (Ireland)

  $244.6

  ▼ 2.59%
  Market cap $15.80BP/E 16.97
  $123.88$266.38
• BBIO

  BridgeBio Pharma Inc. Common Stock

  $76.62

  ▼ 2.62%
  Market cap $15.65BP/E —
  $48.78$93.42
• ASND

  Ascendis Pharma A/S Ordinary Share

  $248.06

  ▼ 0.52%
  Market cap $15.09BP/E 26.94
  $186.05$282.15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona
  benzinga · 8/28/2026
• Tracking Renaissance Technologies (RenTec) 13F Portfolio - Q2 2026 Update
  SeekingAlpha · 8/21/2026
• United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns
  ChartMill · 8/20/2026
• United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
  Benzinga · 8/17/2026
• LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
  Yahoo · 8/13/2026
• United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play
  ChartMill · 8/13/2026
• BETA Technologies, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/13/2026
• BETA Technologies Inc (BETA) (Q2 2026) Earnings Call Highlights: Revenue Surges 146% as ...
  Yahoo · 8/12/2026
• Why No. 2 IBD 50 Stock, Liquidia, Dropped Despite Its Sales Beat
  Yahoo · 8/12/2026

• Martine A. Rothblatt · August 13, 2026 · Option Exercise

  9.5K @ $135.42
• Martine A. Rothblatt · August 13, 2026 · Sale

  240 @ $512.36
• Martine A. Rothblatt · August 13, 2026 · Sale

  160 @ $503.83
• Martine A. Rothblatt · August 13, 2026 · Sale

  200 @ $509.92
• Martine A. Rothblatt · August 13, 2026 · Sale

  640 @ $508.76
• Martine A. Rothblatt · August 13, 2026 · Sale

  920 @ $507.14
• Martine A. Rothblatt · August 13, 2026 · Sale

  1.7K @ $506.16
• Martine A. Rothblatt · August 13, 2026 · Sale

  961 @ $505.18
• Martine A. Rothblatt · August 13, 2026 · Sale

  440 @ $502.93
• Martine A. Rothblatt · August 13, 2026 · Sale

  1.5K @ $501.88
• Martine A. Rothblatt · August 13, 2026 · Sale

  1.3K @ $500.93
• Martine A. Rothblatt · August 13, 2026 · Sale

  1.3K @ $500.08
• Martine A. Rothblatt · August 12, 2026 · Option Exercise

  9.5K @ $135.42
• Martine A. Rothblatt · August 12, 2026 · Sale

  41 @ $520.96
• Martine A. Rothblatt · August 12, 2026 · Sale

  679 @ $520.38

Institutional Ownership

March 31, 2026

Total shares held

42.45M

Total value held

$23.63B

Institutional holders

838